NCT05879627View on ClinicalTrials.gov

To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

250

Participants

Timeline

Start Date

January 17, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

July 1, 2026

Conditions

Advanced Solid Tumors

Interventions

DRUG

BAT8007 for injection

Intravenous infusion: once every three weeks.The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30\~120 minutes.

Trial Locations (1)

Unknown

Sun Yat-sen University Cancer Center, Guangzhou